

RESEARCH NOTE

Open Access



Effects of a naturally occurring amino acid substitution in bovine PrP: a model for inherited prion disease in a natural host species

Catherine E. Vrentas¹, Justin J. Greenlee¹, Gregory H. Foster¹, James West², Marianna M. Jahnke², Mark T. Schmidt¹ and Eric M. Nicholson^{1*} 

Abstract

Objective: The most common hereditary prion disease is human Creutzfeldt-Jakob disease (CJD), associated with a mutation in the prion gene resulting in a glutamic acid to lysine substitution at position 200 (E200K) in the prion protein. Models of E200K CJD in transgenic mice have proven interesting but have limitations including inconsistencies in disease presentation, requirement for mixed species chimeric protein constructs, and the relatively short life span and time to disease onset in rodents. These factors limit research on the mechanism by which the mutation drives disease development. Therefore, our objective was to provide the first assessment of cattle carrying the homologous mutation, E211K, as a system for investigating longer-term disease mechanisms. The E211K substitution was associated with a case of bovine spongiform encephalopathy from 2006.

Results: We assessed the molecular properties of bovine E211K prion protein, characterized the molecular genetics of a population of cattle E211K carriers (offspring of the original EK₂₁₁ cow) in relation to findings in humans, and generated preliminary evidence that the impacts of copper-induced oxidative stress may be different in cattle as compared to observations in transgenic mouse models. The cattle E211K system provides the opportunity for future analysis of physiological changes over time.

Keywords: Prion, CJD, Creutzfeldt-Jakob disease, E200K, E211K, Cattle, *Bos taurus*, BSE, PrP, PRNP

Introduction

Background

Prion diseases are fatal diseases of the nervous system associated with misfolding of the prion protein (PrP^C) into a more protease-resistant conformation (PrP^{Sc}). In humans, a subset of disease is derived from the inheritance of mutations in the prion gene (*PRNP*). The most common form of hereditary Creutzfeldt-Jakob disease (CJD) is caused by a mutation in the prion gene (*PRNP*) resulting in a glutamic acid to lysine substitution at

amino acid 200 (E200 K) [1–3]. However, the exact basis by which the E200K change leads to PrP^{Sc} accumulation and/or disease is unknown. The E200K change only slightly affects conformational stability of human recombinant PrP [4]. It has been proposed that an increase in hydrophobic surface exposure in E200 K protein contributes to aggregation and cellular toxicity [5].

Studies of human E200K carriers suggest a role for factors beyond simply the presence of the primary *PRNP* mutation in modulating CJD progression. In the Libyan Jewish population, there is a large variation in age of symptom onset among carriers (40–80+) [6]. Rates of CJD penetrance also vary between populations, from 67 to 96% [7, 8]. Notably, expression of the wild-type allele was higher in the majority of healthy middle-aged E200K

*Correspondence: eric.nicholson@ars.usda.gov

¹ United States Department of Agriculture, Agricultural Research Service, National Animal Disease Center, Ames, IA, USA

Full list of author information is available at the end of the article

carriers in a Libyan population, with an E:K transcript ratio of 50:1 in some individuals, whereas CJD-affected E200K heterozygotes primarily exhibited equivalent ratios of expression [9].

Recent work in a mouse model of E200K prion disease in which transgenic mice (carrying chimeric human/mouse *PRNP*) develop neurological disease and accumulate PrP^{Sc} suggests that oxidative stress synergistically interacts with the E200K mutation to induce disease. The E200K mutation impairs copper binding and is associated with increased copper sensitivity in cultured E200K fibroblasts and acceleration of disease in E200K mice dosed with copper [10]. Oxidative damage induced by reactive oxygen species generated by free copper ions [11] may also interact with the susceptibility of E200K PrP^C to be spontaneously oxidized at methionine residues [12]. Characteristics of other mouse models for inherited prion disease are reviewed in [13].

Until recently, no examples of naturally occurring, inherited prion disease were known to exist in non-human species. In 2006, a 10-year old crossbred (*Bos indicus* × *Bos taurus*) United States beef cow was diagnosed with H-type BSE. This animal possessed a non-synonymous polymorphism in *PRNP*, resulting in the change of amino acid 211 from glutamic acid to lysine (E211K) [14]. As E211 is homologous to the human E200 residue, this animal was proposed to represent the first example of a genetically-based TSE in livestock. A female offspring of this BSE case also carried the E211K mutation [15].

Rationale

In order to develop therapeutic strategies against inherited prion diseases, an understanding of specific mechanisms resulting in disease development over time is important. Due to the long-term nature of many environmental stressors such as accumulation of oxidative damage in tissues, an experimental system is needed that allows for pre-symptomatic investigation in a species that is a natural host of prion diseases and has a lifespan significantly longer than that of a laboratory mouse. Therefore, here, we provide an initial characterization of the first natural host experimental system for genetic prion disease: heterozygous carriers of the analogous mutation in cattle PrP, E211K. Specifically, we consider characteristics of EK₂₁₁ cattle that are not currently exhibiting disease signs (2–4 years of age), as a means of understanding preclinical phenotypes that may contribute to disease pathology in mammals with the 200K/211K mutation.

Main text

Origin and propagation of E211K cattle herd

The EK₂₁₁ female offspring, a *Bos indicus* crossbred animal described in detail in [15], was used to produce a


small herd of heterozygous cattle by superovulation and embryo transfer, which remains under observation at the USDA. EK₂₁₁ animals were bred by artificial insemination to generate the first KK₂₁₁ (homozygous mutant) calf in 2013. Sibling wild-type calves (EE₂₁₁ homozygotes) were produced and characterized in parallel.

In the E200K mouse model, mice carrying the mutant allele on either a wild-type or null *PRNP* background exhibited onset of terminal illness at approximately 7 months of age [16], about a quarter of the life span of mice with the C57BL/6 J background (Jackson Laboratories). The disease endpoint of the 2006 BSE case represents approximately half the maximum lifespan of beef cattle (≈ 20 years), consistent with humans who develop disease in middle/late middle age. None of the monitored EK₂₁₁ cattle have yet exhibited neurological signs.

Evaluation of E211K protein folding and stability

In order to evaluate the properties of the bovine E211K protein as compared to the human E200K protein, we compared stability characteristics of wild-type (glutamic acid residue at position 211) bovine recombinant PrP^C to E211K bovine recombinant PrP^C (representing residues 25–241; see Additional file 1 for detailed methods). When loss of secondary structure upon melting was monitored by loss of circular dichroism signal at 222 nm, the T_m (temperature at the unfolding midpoint) of bovine E211K protein (65.7 ± 0.2 °C) was lower than that of the wild-type protein (68.5 ± 0.3 °C; Fig. 1a), similar to previous findings for N-terminally truncated versions of recombinant human E200K (T_m = 67.0 ± 0.9 °C) and wild-type (T_m = 70.2 ± 0.1 °C) proteins [4]. Differences in ΔH_m (change in enthalpy upon unfolding determined at the midpoint of unfolding) between wild-type and E211K bovine PrP were unremarkable (ΔH_m (wild-type) = 63.6 ± 5 kcal mol⁻¹; ΔH_m (E211K) = 66.3 ± 2 kcal mol⁻¹).

Using guanidine hydrochloride (GdnHCl) unfolding at 23 °C, the ΔG_{H₂O} value of unfolding (measurement of the thermodynamic stability of the protein) for wild-type bovine protein was 5.0 ± 0.2 kcal mol⁻¹ (m value = 2.3 ± 0.1 kcal mol⁻¹M⁻¹; [D]_{1/2} = 2.2 ± 0.1 M GdnHCl), within error of that determined for E211K bovine protein (ΔG_{H₂O} = 4.9 ± 0.1 kcal mol⁻¹, m value = 2.4 ± 0.04 kcal mol⁻¹M⁻¹; [D]_{1/2} = 2.1 ± 0.01 M GdnHCl) (Fig. 1b). Similarly, for human full-length recombinant protein, ΔG_{H₂O} values for wild-type and E200K proteins were not significantly different at 22 °C [17]. At 39 °C (cattle body temperature), we did observe higher stability of the wild-type (ΔG_{H₂O} = 5.0 ± 0.4 kcal mol⁻¹; m-value = 2.9 ± 0.2 kcal mol⁻¹M⁻¹; [D]_{1/2} = 1.7 ± 0.1 M GdnHCl) as compared to E211K (ΔG_{H₂O} = 3.9 ± 0.1 kcal mol⁻¹; m-value = 2.6 ± 0.1 kcal mol⁻¹M⁻¹, [D]_{1/2} = 1.6 ± 0.03 M



GdnHCl) bovine prion protein. Overall, the relative properties of the bovine wild-type and mutant proteins are consistent with those of the human pair of proteins [4].

Molecular genetics of EK₂₁₁ cattle

Previous findings suggested a role for gene regulation in modulating development of prion disease in E200K CJD [18]. Such a modulation in cattle could be regulated through a 23 base pair (bp) insertion/deletion (indel) polymorphism in the promoter region and a 12 bp indel in exon 1 of *PRNP*. These sites have been implicated in BSE, where deletion at each site was over-represented in BSE cases as opposed to healthy animals, presumably by modulation of *PRNP* expression [19, 20]. We characterized the promoter region in EK₂₁₁ animals via analysis

of genomic DNA from the offspring of the U.S. 2006 case, which was heterozygous for both the 23 bp and the 12 bp indels. To identify the haplotype associated with K₂₁₁, a single ovum was isolated from the offspring, and its genome was amplified. Sequencing of *PRNP* revealed the ovum was E₂₁₁, and sizes of *PRNP* PCR products indicated that DNA from the ovum carried insertions at both the 23 and 12 bp indel sites. Therefore, the K₂₁₁ allele must be associated with the 23 and 12 bp deletions. Upon birth of the first KK₂₁₁ calf, its *PRNP* promoter was sequenced, confirming the haplotype of the K₂₁₁ allele to be deletions at both sites.

Next, we examined whether any of the heterozygous EK₂₁₁ cattle exhibited disparate levels of expression of the E and K alleles, as was observed in white blood cells of many middle-aged healthy human carriers [18]. One hypothesis is that an imbalance in allelic expression (E > K) earlier in the lifespan delays disease progression. Peripheral blood leukocytes (PBLs) were used as a non-invasive source of mRNA; this cell population has been demonstrated to express appreciable PrP^C in cattle [21]. The E:K allelic ratio was determined by sequencing of PCR-amplified products from reverse-transcribed RNA pools from three EK₂₁₁ cattle 4 years in age, utilizing allele quantification software (Additional file 1). The striking overexpression effect of the wild-type (E) allele in healthy human E200K carriers was not observed for any of these cattle samples (Table 1).

Healthy human E200K carriers also exhibit higher overall *PRNP* expression as compared to both EE₂₀₀ individuals and affected EK₂₀₀ individuals, leading to the suggestion that increased wild-type allele expression could have a protective effect [18]. To determine if these *PRNP* expression characteristics were also observed in EK₂₁₁ heterozygous cattle, we measured the level of overall *PRNP* gene expression in each of three EK₂₁₁ cattle (2–3 years of age) as compared to the level in each of three age-matched EE₂₁₁ cattle. PBLs were again utilized as a non-invasive source of cells. The level of *PRNP* expression (relative to *ACTB*; ΔC_t) was only 5% higher in EE₂₁₁ as compared to EK₂₁₁ animals (Table 1; Additional file 2), consistent with very small differences in expression between the groups.

Assessing oxidative stress in EK₂₁₁ cattle

Finally, we utilized our cattle herd to examine the proposal that mammals carrying the E200K/E211K mutation are subject to increased oxidative stress. Mutant mouse fibroblasts have an increased sensitivity to copper in cell culture [10]. Our qRT-PCR results demonstrate expression of *PRNP* RNA in PBLs, confirming previous work demonstrating that *PRNP* expression in cattle PBLs is as high as that in fibroblasts [21]. PBLs isolated

Table 1 Summary of characterization of properties of EK₂₁₁ cattle

1	2	3	4	5	6	7	8
Calf number	Genotype	% WT Allele (G)/% K Allele (A)	C _t (PRNP)	C _t (ACTB)	ΔC _t	Plasma TBARS: OD ₅₄₀ reading	Plasma SOD level (U/ml)
#79	EE ₂₁₁	–	30.4	19.6	10.8	0.18	0.036
#84	EK ₂₁₁	54/46	30.0	19.0	11.0	0.19	0.040
#85	EE ₂₁₁	–	30.0	19.2	10.8	0.15	0.046
#86	EE ₂₁₁	–	30.9	20.3	10.6	0.20	0.046
#87	EK ₂₁₁	54/46	30.0	18.9	11.2	0.20	0.055
#88	EK ₂₁₁	52/48	30.6	18.9	11.6	0.17	0.054
EE ₂₁₁ Average					10.8 ± 0.1	0.18 ± 0.03	0.043 ± 0.007
EK ₂₁₁ Average					11.3 ± 0.3	0.19 ± 0.02	0.052 ± 0.008

Column 3 presents the results of allele expression analysis of RNA from EK₂₁₁ cattle PBLs. Ratios were assessed by analysis of sequencing reactions of PCR amplicons of the region around codon 211 in *PRNP* cDNA, using QSVAnalyzer as described in additional methods (Additional file 1). Cattle were 48 months of age at the time of this analysis. **Columns 4–6** represent the results of qRT-PCR analysis of *PRNP* expression levels in both EE₂₁₁ and EK₂₁₁ cattle PBLs, with **Column 6** indicating the $\Delta C_t = C_t(\text{PRNP}) - C_t(\text{ACTB})$. **Column 7** depicts results of TBARS readings on peripheral blood plasma samples. TBARS numbers reflect the OD₅₄₀ of the cattle plasma samples as measured by the TBARS Kit from Cayman Chemical; due to interference from a separate absorbance peak in these samples, values are reported here as absorbance at 540 nm as opposed to a quantitative value based on the standard curve. **Column 8** depicts the results of SOD (Superoxide Dismutase) assays on peripheral blood plasma samples. SOD values are expressed in U/ml as derived from a standard curve generated with the SOD Assay Kit from Cayman Chemical. For columns 4–8, animals were 26 months of age at the time of analysis, with the exception of animal #79, which was 32 months at the time. The bottom two rows depict average values across biological replicates for parameters, expressed \pm the 95% CI (confidence interval) in each case. (We note that we assume a normal distribution to calculate the CI; due to the unique nature of this cattle population, a small number of EK₂₁₁ animals are available for testing, precluding more in-depth examinations of normality). The SOD assay on peripheral blood plasma was also completed on the offspring of the U.S. 2006 H-type BSE case (level = 0.057), and this value was included in the EK₂₁₁ cattle average (**Column 8**).

from EK₂₁₁ and EE₂₁₁ cattle were treated with copper concentrations (selected to correspond to the range in [10]), followed by measurement of cell viability by MTT assay. We did not observe a difference in copper toxicity, and by extension the level of metal-induced stress experienced, between genotypes (Fig. 2). The profile of copper sensitivity of cells from a KK₂₁₁ calf was comparable to that for an EE₂₁₁ calf tested in parallel (Fig. 2, inset), suggesting that the increased mutant copper sensitivity observed in humans is not recapitulated in this cattle system.

Finally, to determine if the E211K polymorphism is causing a detectable level of general oxidative stress in preclinical cattle, we analyzed peripheral blood samples for molecular markers of systemic oxidative stress. Levels of superoxide dismutase (SOD) in blood plasma were comparable between EE₂₁₁ and EK₂₁₁ cattle that were 2–3 years of age (Table 1); a 20% increase was observed in the EK₂₁₁ group, but this difference did not reach the level of statistical significance (Additional file 2). A colorimetric TBARS assay, which detects lipid peroxidation resulting from oxidative stress, was also performed on the plasma samples. No genotype-dependent differences were noted (Table 1). Therefore, while it is possible that signs of oxidative damage in the blood will increase over time, young, preclinical cattle heterozygotes do not exhibit large increases in blood markers of systemic oxidative stress (Additional file 2).




Fig. 2 Test of copper sensitivity in PBLs from wild-type and EK₂₁₁ cattle. PBLs isolated from each calf were treated with increasing concentrations of Cu²⁺ for 48 h, and cell viability was determined by the MTT assay. MTT values from triplicate wells for each animal were averaged, followed by averaging across genotypes to generate the displayed curves (the animals used were the same 6 as in Table 1, with the same bleed dates); data are displayed as the average MTT reading as a fraction of the average reading at 0 μM Cu²⁺, and the error bars represent the 95% CI for the calves of each genotype. Inset: Comparison of single KK₂₁₁ calf (filled circles) to EE₂₁₁ calf (open circles). Data analysis and axis labels are identical to the main panel

Limitations

This study describes the first natural host experimental system for genetic prion diseases, including molecular characterization of bovine E211K recombinant prion

protein and molecular genetic experiments on EK₂₁₁ cattle.

Limitations include the small sample size of these (rare) cattle, therefore limiting the ability to assess normality of parameters and limiting statistical power. However, in Additional file 2, we present t test comparisons and predictions of statistical power to provide information about the magnitude of differences in physiological parameters predicted to be detectable in further experiments with this herd. Additionally, unlike the case of the E200K prion mouse model (for which many *PRNP*-null mice exist), *PRNP*-null bovine cells were not available for comparative analysis.

Future characterization of the cattle over time, including analysis of parameters assessed in this study coupled with analysis of necropsied animals, will afford us the ability to assess molecular mechanisms of pathology. For example, brain tissue samples may reveal evidence of oxidative damage not perceivable in peripheral blood samples.

Additional files

Additional file 1. Additional methods. More detailed information about methodologies used to generate data in Fig. 1, Fig. 2, and Table 1, including primers, qRT-PCR amplification conditions, and cycling information, as well as information about cell assays and recombinant prion protein purification.

Additional file 2. Additional Statistical Analysis. Additional description of statistical tests completed on the data, potential statistical limitations and their implications, and prospective statistical power analyses for assessment of effects of the 200K mutation.

Abbreviations

PRNP: prion gene; CJD: Creutzfeldt-Jakob disease; PrP: prion protei; T_m : temperature at the unfolding midpoint; ΔH_m : change in enthalpy upon unfolding determined at the midpoint of unfolding; bp: base pair; PBLs: peripheral blood leukocytes; SOD: superoxide dismutase.

Authors' contributions

CEV designed the study, performed experiments, and prepared the manuscript; JJG contributed animal specimens for analysis, provided clinical information and interpretation, and helped draft the manuscript; GF designed and performed molecular genetics experiments; JKW and MMJ bred the experimental cattle population; MTS designed and performed recombinant protein experiments; and EMN conceived experiments and helped draft the manuscript. All authors read and approved the final manuscript.

Authors' information

Disclaimer: Mention of trade names or commercial products in this article is solely for the purpose of providing specific information and does not imply recommendation or endorsement by the U.S. Department of Agriculture. USDA is an equal opportunity employer.

Author details

¹ United States Department of Agriculture, Agricultural Research Service, National Animal Disease Center, Ames, IA, USA. ² Department of Veterinary Diagnostic and Production Animal Medicine, College of Veterinary Medicine, Iowa State University, Ames, IA, USA.

Acknowledgements

We are grateful to Semakaleng Lebepe-Mazur, Andrew Gibson, Kevin Hassall, Leisa Mandell, and Trudy Tatum for their excellent technical contributions to the animal and laboratory experiments at the National Animal Disease Center, and to Dr. Marcus Kehrlri for helpful technical discussions.

Competing interests

The authors declare that they have no competing interests.

Availability of data and materials

No applicable data. Relevant materials (e.g., primer information) is available upon request to the corresponding author.

Consent for publication

Not applicable.

Ethics approval and consent to participate

All animal experiments were carried out in accordance with the Guide for the Care and Use of Laboratory Animals (Institute of Laboratory Animal Resources, National Academy of Sciences, Washington, DC) and the Guide for the Care and Use of Agricultural Animals in Research and Teaching (Federation of Animal Science Societies, Champaign, IL) under the approval of the Institutional Animal Care and Use Committee of the National Animal Disease Center (protocol numbers 2415 and 2618).

Funding

This study was funded by intramural funding of the Agricultural Research Service, U.S. Department of Agriculture.

Publisher's Note

Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

Received: 20 October 2017 Accepted: 13 December 2017

Published online: 20 December 2017

References

- Hsiao K, Meiner Z, Kahana E, Cass C, Kahana I, Avrahami D, et al. Mutation of the prion protein in Libyan Jews with Creutzfeldt-Jakob disease. *N Engl J Med*. 1991;324:1091–7.
- D'Alessandro M, Petraroli R, Ladogana A, Pocchiari M. High incidence of Creutzfeldt-Jakob disease in rural Calabria, Italy. *Lancet*. 1998;352:1989–90.
- Mitrova E, Belay G. Creutzfeldt-Jakob disease with E200K mutation in Slovakia: characterization and development. *Acta Virol*. 2002;46:31–9.
- Swietnicki W, Petersen RB, Gambetti P, Surewicz WK. Familial mutations and the thermodynamic stability of the recombinant human prion protein. *J Biol Chem*. 1998;273:31048–52.
- Corsaro A, Thellung S, Bucciarelli T, Scotti L, Chiovitti K, Villa V, et al. High hydrophobic amino acid exposure is responsible of the neurotoxic effects induced by E200K or D202N disease-related mutations of the human prion protein. *Int J Biochem Cell Bio*. 2011;43:372–82.
- Chapman J, Ben-Israel J, Goldhammer Y, Korczyn AD. The risk of developing Creutzfeldt-Jakob disease in subjects with the *PRNP* gene codon 200 point mutation. *Neurology*. 1994;44:1683–6.
- Ladogana A, Puopolo M, Poggi A, Almonti S, Mellina V, et al. High incidence of genetic human transmissible spongiform encephalopathies in Italy. *Neurology*. 2005;64:1592–7.
- Spudich S, Mastrianni JA, Wrensch M, Gabizon R, Meiner Z, Kahana I, et al. Complete penetrance of Creutzfeldt-Jakob disease in Libyan Jews carrying the E200K mutation in the prion protein gene. *Mol Med*. 1995;1:607–13.
- Rosenmann R, Halimi M, Kahana I, Biran I, Gabizon R. Differential allelic expression of PrP mRNA in carriers of the E200K mutation. *Neurology*. 1997;49:851–6.

10. Canello T, Friedman-Levi Y, Mizrahi M, Binyamin O, Cohen E, Frid K, et al. Copper is toxic to PrP-ablated mice and exacerbates disease in a mouse model of E200K genetic prion disease. *Neurobiol Dis.* 2012;45:1010–7.
11. Gaetke LM, Chow CK. Copper toxicity, oxidative stress, and antioxidant nutrients. *Toxicology.* 2003;189:147–63.
12. Canello T, Frid K, Gabizon R, Lisa S, Friedler A, Moskovitz J, et al. Oxidation of Helix-3 methionines precedes the formation of PK resistant PrP. *PLoS Pathog.* 2010;6:e1000977.
13. Watts JC, Prusiner SB. Experimental models of inherited PrP prion diseases. *Cold Spring Harb Perspect Med.* 2017;7(11). <https://doi.org/10.1101/cshperspect.a027151>.
14. Richt JA, Hall SM. BSE case associated with prion protein gene mutation. *PLoS Pathog.* 2008;4:e1000156.
15. Nicholson EM, Brunelle BW, Richt JA, Kehrli ME Jr, Greenlee J. Identification of a heritable polymorphism in bovine *PRNP* associated with genetic transmissible spongiform encephalopathy: evidence of heritable BSE. *PLoS ONE.* 2008;3:e2912.
16. Friedman-Levi Y, Mizrahi M, Frid K, Binyamin O, Gabizon R. PrPST, a soluble, protease resistant and truncated PrP form features in the pathogenesis of a genetic prion disease. *PLoS ONE.* 2013;8:e69583.
17. Cereghetti GM, Schweiger A, Glockshuber R, Van Doorslaer S. Stability and Cu(II) binding of prion protein variants related to inherited human prion diseases. *Biophys J.* 2003;84:1985–97.
18. Rosenmann R, Halimi M, Kahana I, Biran I, Gabizon R. Differential allelic expression of PrP mRNA in carriers of the E200K mutation. *Neurology.* 1997;49:851–6.
19. Sander P, Hamann H, Drogemuller C, Kashkevich K, Schiebel K, Leeb T. Bovine prion protein gene (*PRNP*) promoter polymorphisms modulate *PRNP* expression and may be responsible for differences in bovine spongiform encephalopathy susceptibility. *J Biol Chem.* 2005;280:37408–14.
20. Jüling K, Schwarzenbacher H, Williams JL, Fries R. A major genetic component of BSE susceptibility. *BMC Biol.* 2006;4:33.
21. Richt JA, Kasinathan P, Hamir AN, Sathiyaseelan T, Vargas F, Sathiyaseelan J, et al. Production of cattle lacking prion protein. *Nat Biotechnol.* 2007;25:132–8.

Submit your next manuscript to BioMed Central and we will help you at every step:

- We accept pre-submission inquiries
- Our selector tool helps you to find the most relevant journal
- We provide round the clock customer support
- Convenient online submission
- Thorough peer review
- Inclusion in PubMed and all major indexing services
- Maximum visibility for your research

Submit your manuscript at
www.biomedcentral.com/submit

